Publication | Closed Access

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial

Pretreated PatientsOncologyNcic Ctg Br.26Clinical TrialsImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentMedicineRadiation OncologyLung CancerMolecular OncologyHealth Sciences